NGAM Advisors L.P. reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.0% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 107,507 shares of the biopharmaceutical company’s stock after selling 1,061 shares during the quarter. NGAM Advisors L.P.’s holdings in Gilead Sciences were worth $7,609,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently made changes to their positions in GILD. Keel Point LLC grew its position in shares of Gilead Sciences by 0.4% during the 1st quarter. Keel Point LLC now owns 3,111 shares of the biopharmaceutical company’s stock worth $211,000 after buying an additional 11 shares during the period. West Oak Capital LLC grew its position in shares of Gilead Sciences by 0.7% during the 2nd quarter. West Oak Capital LLC now owns 4,666 shares of the biopharmaceutical company’s stock worth $330,000 after buying an additional 32 shares during the period. First Heartland Consultants Inc. grew its position in shares of Gilead Sciences by 0.4% during the 2nd quarter. First Heartland Consultants Inc. now owns 8,927 shares of the biopharmaceutical company’s stock worth $632,000 after buying an additional 39 shares during the period. Westover Capital Advisors LLC grew its position in shares of Gilead Sciences by 0.8% during the 1st quarter. Westover Capital Advisors LLC now owns 5,563 shares of the biopharmaceutical company’s stock worth $378,000 after buying an additional 46 shares during the period. Finally, Abner Herrman & Brock LLC grew its position in shares of Gilead Sciences by 0.5% during the 1st quarter. Abner Herrman & Brock LLC now owns 10,202 shares of the biopharmaceutical company’s stock worth $693,000 after buying an additional 50 shares during the period. 74.05% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “NGAM Advisors L.P. Sells 1,061 Shares of Gilead Sciences, Inc. (GILD)” was posted by Daily Political and is the property of of Daily Political. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://www.dailypolitical.com/2017/09/17/ngam-advisors-l-p-sells-1061-shares-of-gilead-sciences-inc-gild.html.

Gilead Sciences, Inc. (NASDAQ:GILD) opened at 82.36 on Friday. The firm’s 50-day moving average price is $77.16 and its 200 day moving average price is $70.20. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $86.27. The company has a market cap of $107.56 billion, a PE ratio of 8.95 and a beta of 1.19.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The business had revenue of $7.14 billion for the quarter, compared to analysts’ expectations of $6.35 billion. During the same quarter in the previous year, the firm earned $3.08 earnings per share. The business’s revenue was down 8.2% on a year-over-year basis. On average, equities analysts predict that Gilead Sciences, Inc. will post $8.75 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be paid a $0.52 dividend. The ex-dividend date is Thursday, September 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.53%. Gilead Sciences’s payout ratio is presently 22.58%.

In other Gilead Sciences news, EVP Gregg H. Alton sold 5,000 shares of the business’s stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $71.06, for a total value of $355,300.00. Following the sale, the executive vice president now directly owns 102,988 shares in the company, valued at $7,318,327.28. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Gregg H. Alton sold 40,000 shares of the business’s stock in a transaction on Friday, July 21st. The shares were sold at an average price of $74.00, for a total value of $2,960,000.00. Following the completion of the sale, the executive vice president now owns 137,488 shares in the company, valued at $10,174,112. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 466,819 shares of company stock worth $36,740,240. Corporate insiders own 1.30% of the company’s stock.

Several equities analysts have recently issued reports on GILD shares. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research report on Monday, August 28th. Vetr upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $89.27 price objective for the company in a research report on Wednesday, September 6th. Maxim Group reiterated a “hold” rating on shares of Gilead Sciences in a research report on Thursday, July 27th. ValuEngine lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. Finally, BMO Capital Markets reiterated an “outperform” rating and issued a $82.00 price objective (up from $72.00) on shares of Gilead Sciences in a research report on Thursday, July 27th. Eleven investment analysts have rated the stock with a hold rating and twenty have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $83.79.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.